Abstract: Acetylcholinesterase (AChE) inhibitors are an important class of medicinal agents useful for the treatment of Alzheimer's disease, glaucoma, myasthenia gravis and for the recovery of neuromuscular block in surgery. To rationalize the structural requirements of AChE inhibitors we attempt to derive a coherent AChE-inhibitor recognition pattern based on literature data of molecular modelling and quantitative structure-activity relationship (QSAR) analyses. These data are summarised from nearly all therapeutically important chemical classes of reversible AChE inhibitors, e.g., derivatives of physostigmine, tacrine, donepezil and huperzine A. Interactions observed from X-ray crystallography between these inhibitors and AChE have also been incorporated and compared with modelling and QSAR results. It is concluded that hydrophobicity and the presence of an ionizable nitrogen are the pre-requisites for the inhibitors to interact with AChE. However the mode of interaction i.e., the 3-dimensional (3D) positioning of the inhibitor in the active site of the enzyme varies among different chemical classes. It is also recognised that water molecules play crucial roles in defining these different 3D positioning. The information on AChE-inhibitor interactions provided should be useful for future discovery of new chemical classes of AChE inhibitors, especially from De Novo design and hybrid construction.
Introduction
The medicinal use of AChE inhibitors has been known even longer than the enzyme itself. Already in the mid-nineteenth century, physostigmine was recognised to cause constriction of the pupil and contraction of the ciliary muscle, thus improving the drainage of aqueous humour [4] . Today, the main clinical uses of AChE inhibitors are in anaesthesia [5] , in the treatment of myasthenia gravis [6] , glaucoma [7] and Alzheimer's disease [8] . Table 1 lists a few more recent examples of AChE inhibitors and their clinical indications. As more physiological functions of ACh are being elucidated, there should arise more therapeutic opportunities for AChE inhibitors [9] . Acetylcholinesterase (EC 3.1.1.7, AChE) is probably one of the earliest enzymes to have been studied for its pharmacological functions. As early as 1914, Dale had already suggested that physostigmine (1 ), a naturally occurring alkaloid from the Calabar bean, inhibited an enzyme that catalysed the breakdown of choline esters [1] . Indeed, AChE's vital function is the hydrolytic destruction of the neurotransmitter acetylcholine (ACh), which terminates the impulse transmission at cholinergic synapses. Through activation of either the ionotropic nicotinic receptors or the metabotropic muscarinic receptors, ACh exerts many physiological functions both in the periphery and the central nervous system (CNS) [2, 3] , e.g., smooth muscle contraction, modulation of cardiac rate and force, motor control, temperature regulation, memory and pain modulation, etc. Inhibition of AChE results in the cumulation of ACh and enhanced cholinergic transmission, and has long been an attractive target for drug development.
The purpose of this paper is to review literature data on molecular interactions between AChE and its inhibitors, derived from molecular modelling and quantitative structure-activity relationship (QSAR) analyses. Since irreversible AChE inhibitors are therapeutically less useful, reports on these inhibitors are not included in this review. Interested readers are referred to other sources [10] [11] [12] . Attempts will be made to compare and rationalize modelling and QSAR results with those observed from X-ray crystallography so to derive a coherent AChE-inhibitor recognition pattern. This hopefully would be useful for the future design of new AChE inhibitors. 
Structure and Catalytic Mechanism of AChE
three tetramers of up to twelve catalytic subunits linked to a collagen tail through disulphide bridges. A second class, commonly called the globular forms (G n ), exists as monomeric (G 1 ), dimeric (G 2 ) and tetrameric (G 4 ) assemblies of catalytic subunits. Different forms of AChE exhibit tissue-specific distribution, e.g., asymmetric forms are concentrated in neuromuscular junctions of mammalian skeletal muscle and in the electric organs of rays and eels whereas the major AChE forms in the CNS are the amphiphilic globular tetramer (G 4 ) [16] .
AChE is bound to the basement membrane in the synaptic cleft at cholinergic synapses. The soluble form of AChE is also present in cholinergic nerve terminals, where it seems to have a role in regulating the free ACh concentration, and from which it may be secreted, the function of which is so far unclear [13] . It is important to note that there is a distinct type of soluble cholinesterase, butyrylcholinesterase (EC 3.1.1.8, BChE), which has a closely related molecular structure (~53% sequence homology) to AChE but different distribution, substrate specificity and functions. BChE also hydrolyses ACh but unlike AChE it has a much broader substrate specificity and broader distribution. The precise physiological function of BChE is still a subject of debate [14] .
It is theoretically possible to selectively inhibit one particular form of AChE, as so claimed for the action of SDZ-ENA 713 (6 ) Two classes of different quaternary structures of AChE exist in synaptic junctional and extrajunctional areas, which are distinguishable by their solubility characteristics and hydrodynamic properties [15] . One class exists as asymmetric forms (A n ) constituted by Table 2 ).
The role of aromatic residues in the gorge may be to facilitate diffusion of the substrate to the active centre (aromatic guidance) [20] . The aromaticity may also preclude the necessity of displacement of slowexchanging water molecules at the base of the cleft upon ligand binding and hence it could simply play a passive role. What is definite is that these aromatic residues play important roles in binding of inhibitors to the active site, as evidenced by the influence of physico-chemical properties of the inhibitors, e.g., hydrophobicity, electronic effects, etc., to their inhibitory potency on the enzyme. Although AChE is polymorphic, activities of catalytic subunits in the asymmetric and globular forms of the enzyme are similar. In 1991, Sussman et al crystallised the glycolipid-anchored homodimer of AChE from Torpedo californica electric organ and reported its three-dimensional structure (at 2.8 Å resolution) [20] . The crystal structure established that the subunits contain 12-stranded mixed β sheet surrounded by 14 α helices. They are ellipsoid in shape (45x60x65 Å) and associate as dimers in a four-helix bundle. A tetramer of Electrophorus electricus AChE has also been crystallised [21] . A low resolution structure revealed a subunit arrangement of a dimer of dimers.
Quantitative and Qualitative SAR of AChE Inhibitors
In the absence of structural details of acetylcholinesterase, traditional quantitative structureactivity relationships (QSAR) have been derived to try to explain variations in biological activities of a given series of acetylcholinesterase inhibitors in terms of physicochemical, structural, and conformational properties of the molecules. Physicochemical properties such as the steric, hydrophobic and electronic features of molecule which have been shown to be important for enzyme-ligand interactions have been extensively employed in QSAR analysis. A variety of descriptors are available to describe these physicochemical properties of molecules. An additional key interaction for AChE inhibition identified from QSAR studies in the design of pesticides and insecticides is a charge transfer interaction between protonated nitrogen and the AChE. QSAR approaches can be employed to guide the design of further potent and biologically attractive AChE inhibitors.
The active site of AChE is a narrow gorge 20 Å in depth and lined up with 14 aromatic residues [20] . At the base of the gorge lies the catalytic triad of Glu327, His440 and Ser200 involving the proton shift from serine OH to the carboxyl of glutamate via the imidazole of histidine. Formation of the acyl enzyme proceeds through formation of a tetrahedral intermediate which relaxes back to the trigonal acyl enzyme. Deacylation also proceeds through a tetrahedral intermediate by attack of the acetyl-AChE bond from an internal water which may be rendered more nucleophilic by a neighbouring carboxyl or imidazole residue.
In this section, we describe the QSAR models and qualitative SAR data for different chemical series of AChE inhibitors. It has been shown that AChE from different species may bear differences and consequently, this may affect the structure-activity relationships derived. On this basis, we have restricted our review to QSAR models generated from species known to exhibit high homology for the active site residues of AChE. For complete details of the range of substituents/analogues and their activities employed in the QSAR models presented, the reader is referred to the original publications.
this QSAR model is that the different R groups force the molecule to adopt different modes of interaction with AChE. The QSAR model does not provide any information about the nature of the interaction between this series of tacrine analogues and AChE. The original authors [22] who synthesized this set of 11 Nmonosubstituted 1,2,3,4-tetrahydro-9-aminoacridines (Dataset 1) also reached similar qualitative relationship between the length of the R group and AChE activity. However, they concluded that given the comparatively small variations (6-fold) in enzyme inhibition for all the various alkyl or arylalkyl substituents, that it may be possible these substituents project away from the protein having little or no effect in binding.
Tacrine
Tacrine (3 ) (Cognex®) was approved as a drug for the treatment of Alzheimer's disease by the FDA in 1993. Despite its wide usage, Tacrine (THA) suffers from dose limiting hepatotoxic complications, slow pharmacokinetics, and a high incidence of side effects. Although large numbers of analogues have been synthesized around tacrine (Fig. (1 ) , R=H, Ki = 0.05µM, electric eel AChE [22] ) in an attempt to identify an analogue with a more favourable in vivo profile, only limited SAR within this series has been reported [22] .
Further analogues of tacrine were synthesized [22] . Analogues in which both amino hydrogens were replaced resulted in a less favourable AChE activity as compared to the monosubstituted analogues. This was attributed to disubstituted analogues preventing the favourable planar-like conformation of the ring system of tacrine being adopted for interaction with the enzyme. Complete aromatization to 9-aminoacridine creates a fully planar system that is found not to affect binding. Similarly, condensation or enlargement of the unsaturated ring or addition of pendant groups onto the aromatic ring are found not to markedly reduce or improve AChE activity. These results suggest a strong hydrophobic interaction between tacrine analogues and AChE . In addition, a basic nitrogen is also suggested to be important for AChE affinity, although this is not reflected in the QSAR model. A series of analogues of 1-hydroxy-tacrine analogues (Fig. (2 ) ) were synthesized (Dataset 2) [24] . Velnacrine (R=R 1 =H, IC 50 = 4µM, Rat Striatum AChE [24] ) 1-hydroxy-tacrine, was identified through modification of tacrine and is currently in Phase III clinical trials [25] . A QSAR model for substituted amino groups on the 9 position of tacrine (Dataset 1) was generated in which a bilinear relationship between the Verloop length parameter L with biological activity is observed [23] . This unusual bilinear equation (Equation (1)) leads to L opt which corresponds to a minimum of activity, rather than maximum in activity. The derived QSAR model represents an inverse bilinear model whose significance and interpretation could not be readily explained. However, it was concluded that the QSAR model suggests that compounds with extreme L values are important for activity. One possible interpretation of The QSAR model generated for the 1-hydroxytacrine analogues, in which substituents have been introduced into 6 position of the tetrahydroacridine, as well as at position 9, is given by Equation (2). As with the previous QSAR model for tacrine analogues (Dataset 1), the correlation equation contains an inverse bilinear term in L. A minimum AChE activity is observed for substituents R with a length L of 5.116 Å. As seen in Equation (2), the indicator variable I-Cl takes a value of 1 when a 6-Cl substituent is present and 0 when 6-Cl is absent. The presence of the 6-Cl substituent at R 1 is shown to be favourable for high AChE activity. Since a limited number of R 1 substituents were considered in the generation of the QSAR model, it is not known whether the 6-Cl substituent forms a favourable hydrophobic or electronic interaction with AChE. The authors who synthesized these 1-hydroxy-tacrine analogues have drawn similar conclusions about the nature of the interaction of these analogues and AChE enzyme [24] .
A QSAR analysis was performed for this series and Equation (3) was derived [23] . Log P' = calculated log P for the ionized compounds.
In this case, the log P' was found to show an inverse linear correlation with AChE activity, thereby suggesting that less hydrophobic compounds are favourable for AChE activity. The original authors [27] who synthesized this series of analogues have suggested that a bulky R 1 group reduces activity by interfering with the binding with the anionic site. It should be noted that for this small dataset, only hydrophobic substituents have been examined. As will be observed with other QSARs for AChE inhibitors, log P' and the shape of R 1 may be highly correlated. In order to determine whether bulkiness and/or hydrophobicity is important, large polar and large hydrophobic substituents would have to be synthesized and tested. For the only polar substituent R 1 = CONHCH 3 , inactivity (IC 50 =3.9µM) may result from the lack of an ionizable nitrogen within this compound.
For both Datasets 1 and 2, QSAR models are generated for which an inverse bilinear relationship between the Verloop length parameter L of R with AChE activity is observed. This suggests that analogues with short R substituents bind favourable to AChE, but as the length of the substituent increases to ≈ 5 Å the interaction becomes unfavourable and then for longer substituents, the interaction with AChE becomes favourable. Secondly, it was found that log P and L are highly correlated. This complicates the interpretation of the QSAR models for tacrine analogues since it could be that the hydrophobic nature of R is important for activity.
A QSAR model has been determined for analogues of physostigmine in which carbamoyl substituents have been modified (Fig. (4 ) ) [27] . Physostigmine (1 ) (Fig. (3 ) , R 1 = CH 3 ) is a natural product which acts as a potent reversible AChE inhibitor. It has been shown to suffer from a short half life, variable bioavailability, and a narrow therapeutic index which accounts for its inconsistent clinical efficacy. In order to improve the in vivo profile of physostigmine whilst retaining its in vitro potency (IC 50 The R 1 substituent is either CH 3 or H and these have been shown in the previous series of N1-substituted analogues of physostigmine (Dataset 3) to be favourable for AChE activity. Therefore only parameters associated with X have been identified as influencing activity (Equation (4) The Verloop L parameter for the morpholinoalkyl substituent has been shown to be highly correlated with log P thus complicating the interpretation of the QSAR. The QSAR model as represented by Equation (5) accounts for only analogues where n ≥ 4 and those analogues with two ionizable centres. A second QSAR model was generated in which the calculated logP' shows a bilinear relationship with activity for all compounds (n=13) of the series (Fig.s (5a) and (5b) ).
This QSAR model suggests that ortho disubstitution in this series is unfavourable for activity. The second term in Equation (4) suggests that polarlike substituents at the para position are favoured. Once again the authors [23] highlight the high correlation between the descriptors for hydrophobicity and shape for both the 4 and 6 positions.
Physostigmine was then modified [28] to incorporate a second ionizable N via a morpholine moiety (Fig. (5 ) ). The authors' rationale for synthesis of such analogues was that at physiological pH, the morpholino nitrogen will be protonated and can interact with putative second anionic site on AChE. It has already been demonstrated that some of the most effective inhibitors are the bis-quaternary compounds [29] such as decathonium. This result suggests that hydrophobicity of the protonated species may play an important role in the interaction with AChE. Given the bilinear nature of the QSAR model, it would appear that there may be two possible different modes of interaction with the enzyme. At short lengths of n with the exception of n=2, the presence of a charged species is unfavourable for AChE activity whereas at large values of n (n >7), a protonated morpholino moiety is favourably positioned for interaction with the proposed second anionic site on enzyme. The former observation is further confirmed by the high AChE affinity of both physostigmine (Fig. (5b) , R=R 1 =CH 3 ) and heptylphysostigmine ( A QSAR model for these analogues (Dataset 5) shows a correlation between the Verloop parameter L for the morpholinoalkyl substituent and biological activity [23] . A series of 8-carba-analogues [30] of physostigmine carrying different substituents on both N atoms and varying the R 2 group on the eseroline ring to be either H or CH 3 were considered for QSAR analysis (Dataset 6). Such analogues were synthesized (Fig. (6 ) ) on the basis that they should exhibit good metabolic stability as compared to physostigmine.
synthesized to explore the SAR of the X substituent ( Fig 
Y=H, n=5 and m=1 n=9 r 2 =0.792 s = 0.308 F 2,18 = 34.37
IC 50 range: 0.045µM -1.35µM (human erythrocyte AChE)
A QSAR model was developed for this series of 15 analogues [23] . B1(R) = Verloop's bulkiness parameter for R substituent; I-Me =1 (R 2 =Me) and 0 (R 2 =H).
Log 1/IC 50 = -0.243 (0.131)logP + 1.594(0.57)F + The B1 parameter for R suggests that linear chain substituents are favoured and that branched substituents decrease activity. The indicator variable IMe at R 2 suggests that the methyl group is favourable for activity. Since only R 2 =CH 3 or H were present within this series, it would appear that the favourable activity of the methyl group may result from a hydrophobic interaction with the enzyme. Unlike the QSAR model derived for Dataset 3 of physostigmine analogues (Equation (3)), the R 1 substituent within this series is not important for activity. Closer examination of the R 1 substituents (R 1 =Me, Et, nPr) present within this series reveals that they are all favourable for activity with the exception of the only bulky R 1 substituent (R 1 =CH 2 Ph) for which the observed AChE activity is unfavourable. Log P -calculated hydrophobicity of the molecule; Felectronic parameter for substituent X.
The QSAR suggests that hydrophilic and electron withdrawing substituents on the phthalimide moiety are favoured for enzyme activity in agreement with the QSAR model derived by Ishihara [31] . The most active compound being X=NO 2 with an IC 50 =0.15µM. The requirement of electron withdrawing substituents was not understood but assumed to be required for an electrostatic interaction with the enzyme. Several parameters such as the size of X substituent do not appear to be important for activity i.e., bulky groups such as X=NHCOCH 3 can be accommodated on the aromatic phthalimide ring without loss of activity. In this series, only substituents at the 5 position have been synthesized and tested for AChE inhibition and therefore the effect of substituents at other positions on the phthalimide moiety remain unknown. Replacement of the benzene group of the phthalimide with cyclohexane leads to a 7-fold drop in activity which cannot be accounted for using Equation (8) . It has been postulated that the cyclohexane may be sterically unfavourable for interaction with AChE.
The QSAR models and qualitative SAR data suggests that physostigmine and carba-8-analogues of physostigmine adopt a similar interaction with the enzyme. Within Dataset 6, it is found that n-Pr as a N1 substituent is tolerated, extrapolation to Dataset 3 would lead to the conclusion that it is the bulkiness of R 1 which is important for AChE activity and not the log P of the compounds. In conclusion, it would appear that steric and/or hydrophobicity of physostigmine analogues are important for AChE activity. It should be noted that a basic nitrogen within these analogues is also important for enzyme inhibition although this is not reflected in the QSAR models (Equations (3)- (7)).
Benzylamines
Further analogues of 2-ω [N-ethyl-N(ω -phenylalkyl)amino]-1H-isoindole-1,3(2H)-diones have been synthesized and tested for AChE inhibition (Fig.  (8 ) ) [31] . The effects of substitution on the phenyl ring of the benzylamino moiety were investigated and are shown in between Y and AChE inhibition given the small number of analogues synthesized within this series (n=8). Replacement of the phenyl ring of the benzylamino moiety with a cyclohexane ring ( Fig. (8 (II) )) lead to a 5-fold drop in the AChE inhibitory potency. This result suggests that a hydrophobic group at this position in the molecule is favourable. The lower affinity of the cyclohexyl derivative may result from the lack of π-π interaction with the enzyme.
On the basis of the hypothesized nature of the interaction of the above series with AChE, Ishihara et al. [32] proceeded to synthesize a new series in which the phthalimide moiety was replaced with 3-arylpropenamide ( Fig. (9 ) ).
A number of analogues (Dataset 8) in which the X and R substituents are varied have been analysed quantitatively using the Hansch-Leo approach (Equation 9). The effect of the chain length of the N-(ω -phenylalkyl)amino moiety as shown in Fig. (8 (III) ) has also been investigated. The optimal spacer length for AChE activity when m=1 (IC 50 =0.15µM). Increasing the chain length m to 2 or 4 leads to a drop in AChE affinity (IC 50 =0.77µM and 1.75µM, respectively). An unusual observation is that in the analogue for which m=3, an affinity (IC 50 =0.16µM) is observed that is comparable to the analogue in which m=1 (IC 50 =0.15µM). One explanation for this observation is that the propyl chain may adopt a conformation that allows good interaction with the enzyme. π -hydrophobic parameter for X, σ -electronic parameter for X, I = 1 (R= CH 3 CO) and 0 (R=H) Equation (9) suggests hydrophilic and electronwithdrawing groups on the aryl moiety and that the presence of the acetyl group for R is favoured for activity. The same conclusions could be drawn from the QSAR model generated by Recanatini et al. [23] for this dataset , the only difference being that logP for the whole molecule was used as a descriptor for hydrophobicity. Equation (9) is similar to Equation (8) thereby suggesting that the X substituents in these two series of benzylamines interact in a similar manner with AChE. The favoured acetyl group for R within this series was attributed to its ability to hydrogen bond to an active site residue of the enzyme. Other analogues were also synthesized within this series to explore its SAR. It was found that these analogues exhibit similar SAR trends to those observed with analogues of the pthalimide-benzylamines (Fig. (7 ) ) e.g the ortho OMe substituent on the phenyl ring of the benzylamino moiety is favoured for AChE inhibition in both series.
Finally the replacement of the N-ethyl group with Nacetyl ( Fig. (8 (IV) ) leads to a significantly loss in AChE activity (IC 50 >100µM), thereby highlighting the importance of the basic nitrogen for interaction with AChE enzyme. Further series of compounds were synthesized in which the phthalimide moiety in Fig. (7 ) was replaced by benzoyl (I), indanone (II) and cyclohexylphenyl ketone (III) moieties [33] as shown in Fig. (10) . The cyclohexylphenyl ketone analogues were found to be inactive and this was attributed to their inability to adopt the bioactive conformation. Both the indanone and benzoyl analogues were found to exhibit activity for AChE. From limited analogues for both these classes of compounds, it was found that they show similar SAR trends to phthalimide series. Furthermore, it was shown that the carbonyl group of the indanone/benzoyl or phthalimide moiety was separately approximately by a 7 carbon chain length from the basic nitrogen. It was postulated that the benzylamine moiety whether linked to a phthalimide, indanone or benzoyl moiety all adopt the same mode of binding with the AChE. No conformational studies have been reported to confirm that all these classes of benzylamines can adopt similar low energy conformations.
•
The distance between the carbonyl and basic nitrogen corresponds to approximately 7 carbon chain length.
Benzylpiperdines
Sugimoto et al. [34] identified a benzylpiperidine, 1-benzyl-4-[2-N-benzoyl (amino)ethyl]piperdine through random screening as a high affinity AChE inhibitor (X=H, IC 50 =0.56µM, Mouse brain AChE). A number of analogues were synthesized (Fig. (11) ); of which a set of analogues were synthesized (Dataset 9) to examine the effect of substitution on the benzamide moiety [23] . In this dataset of analogues, m=1 and Y=H. 
•
The benzylamino moiety binds to anionic site (via basic nitrogen) and a hydrophobic site (close to anionic and esteratic sites) F -electronic field parameter for X; I-P = 1 for para X substituents and 0 for X meta/ortho substituents; I-O =1 for ortho X substituents and 0 for X meta/para substituents. length is n=2 (IC=0.028µM) and that increasing or decreasing this spacer leads to a reduction in activity (n=1, IC 50 = 19µM ; n=3, IC 50 =0.22µM). It was found that para X substituents are favoured for activity whereas ortho substituents are detrimental. In addition, electron withdrawing groups are favoured. This result is similar to QSAR models generated for X substituents in the benzylamines class (Equations (8) and (9)). It has also been shown that a significant QSAR equation containing log P can be derived. However it was found that log P represents an alternative to the electronic parameter F. A wider range of electronic and hydrophobic substituents may result in both effects appearing in a QSAR model. The highest affinity analogue was found to be the 4-pyridyl substituent (IC 50 =0.039µM) within this series. Subsequently, Sugimoto et al [35] (Fig. (11) ) were performed in which the amide group was replaced in the analogue in which m=1 and Y=X=H. It was found that amide nitrogen was not important for AChE inhibition (COCH 2 , IC 50 =0.53µM) and that carbonyl group was crucial for activity (CH 2 NH 2 , IC 50 >4.6µM). Furthermore, it was also found that substitution of the amide hydrogen could lead to an improvement in AChE inhibiton (CONR R=Me, Et, Ph; IC 50 's = 0.17µM, 0.13µM and 0.04µM, respectively). The carbonyl group of the amide is required for activity, presumably for H-bonding to the enzyme.
A QSAR was developed for a set of phthalimides (Dataset 10) where n=2, Y=H and the varying group was X [23] as shown in Fig. (13) . A series of 1-substituted-4-[2-(N-benzoyl-Nmethylamino)ethyl]piperdine analogues were synthesized [34] . Within this series, it was known that the 1-benzyl derivative exhibits an IC 50 of 0.17µM for AChE. For a series of substituted benzyl analogues, no obvious SAR trends were apparent. The cyclohexylmethyl group was found to exhibit moderate AChE activity (IC 50 = 0.41µM). It was also found that increasing the chain length between the basic nitrogen of the piperidine ring and benzyl group from m=1 leads to inactivity. Substituents such as N-benzoyl which remove the basic nitrogen in the piperidine ring led to inactivity (IC 50 = 52µM). In all analogues synthesized within this benzylpiperidine series, the benzamide moiety was always linked to the benzylpiperdine ring via an ethyl linker. The authors suggest that interpretation of the QSAR suggests substituents at the position 4 would favour polar interactions whilst at position 3 (ortho to the phthalimide) bulky substituents are unfavourable. Despite the structural similarity of this series with Datasets 7-9, there appears to be little similarity in the parameters associated with X substituent as being important for AChE inhibition. The lack of an electronic or hydrophobic term in Equation (11) may result from the limited variation in these properties with this series.
In a separate study, Ishihara et al. [33] examined a series of benzylpiperidines linked to a benzoyl moiety (Fig. (12) ). Only a small number of analogues were synthesized. It was found that Y=2-OMe was unfavourable for AChE activity (IC 50 =1.9µM) in the analogue in which n=2 and X=4-pyrrolidino (Fig. (12) ). However, the analogue in which n=2, Y=H and X=4-pyrrolidino, a high affinity of AChE was observed (IC 50 =0.028µM). For X= 4-pyrrolidino and Y=H, the chain length between carbonyl and benzylpiperdine was investigated. It was found that the optimal chain Within this series, analogues (X=NO 2 , Y=H, m=1) were synthesized to allow the investigation of varying linker (n) between the phthalimide moiety and benzylpiperdine. It was found that n=2 (Fig. (13) ) is optimal for activity (IC 50 =0.03µM) whilst decreasing the linker to n=0 or 1, a reduction in activity was observed (IC 50 =2.7µM and 3.0µM, respectively). Further analogues to explore the effect of the Y substituent on activity were synthesized, but no conclusions could be drawn. With introduction of an indanone moiety in place of the phthalimide, E2020 (4) (Donzepil/Aricept ® ) -an AChE inhibitor currently marketed for the treatment of Alzheimers disease was identified [36] [37] [38] . Identification of an achiral AChE inhibitor with a profile similar to E2020 (IC 50 =0.006µM, Mouse brain AChE) (Fig. (14) ) would be desirable. A 3D QSAR studies of E2020 and its analogues were generated using the molecular decompositionrecomposition [38] approach to allow the conformation of substructural fragments within E2020 to be accounted for (Fig. (14) ). For Feature 1 (indanone ring) and Feature 4 (benzylpiperidine) -a variety of descriptors, some of which are dependent on conformation, were examined.
As S 0 for Y becomes larger i.e. the substituents become more bulky, then inhibition decreases. The IX and S 0 terms reflects that increasing the bulk in the region of the benzyl ring leads to a decrease in AChE binding. Furthermore, the HOMO term suggests that a low electronic density in the aromatic ring is important.
In general terms, it is suggested that the aromatic ring of the indanone moiety is less sensitive to substitution as bulky substituents can be tolerated whereas the benzyl group of the benzylpiperidine moiety is sensitive to the size of the para substituent in particular. These results show some agreement with the QSAR (Equations (10) and (11)). Qualitative SAR for the E2020 reveals that the basic nitrogen and the indanone carbonyl are crucial for activity. Replacement of the indanone carbonyl with a hydroxyl (IC 50 =0.3µM) leads to a drop in AChE inhibition. Additionally, the spacers n and m are found to be important for positioning of key groups for interaction with the enzyme. Increasing the chain m >1 in E2020 a reduction in activity is observed, and increasing n to 2 (IC= 0.15µM) or decreasing n to 0 (IC 50 =3.3µM) in E2020 leads to a reduction in activity. The basic nitrogen is required in E2020 for activity as replacement of benzylpiperidine with an N-benzoyl group leads to inactivity. Furthermore, replacement of the benzyl group of the benzylpiperidine with a cyclohexylmethyl (IC 50 =0.009µM) leads to retention of AChE activity. Molecular Shape Analysis (MSA) was employed to determine the active conformation of E2020 [39] . Using a variety of analogues related to E2020 with varying activity, it was predicted that the bioactive conformation has the indanone ring perpendicular to the piperidine ring as found in the X-ray structure of E2020. However, the MSA approach suggests that the benzyl group of benzylpiperidine points towards the carbonyl of the indanone ring rather than being fully extended as in the X-ray structure.
The QSAR suggests that the π electron density for the indanone moiety as reflected by the HOMO and C4 parameters in Equation (12) and that a dipole moment of magnitude between 2.8 and 6.6 Debye are important for activity.
The QSAR of Feature 4 is given by:
The inactivity of some analogues could be explained by their inability to adopt the bioactive conformation or by their lack of key functional groups essential for activity. Such an approach could not explain the activity profile of the analogues in which there is no spacer (n=0 or n=2) between the indanone ring and the piperidine ring. For n=0, it was assumed that inactivity of this analogue results from its inability to adopt a conformation in which its carbonyl and basic nitrogen can overlay with E2020 (n=1). Furthermore, the inactivity of trans-decalin analogue of E2020 could not be explained by its conformational behaviour and was assumed to result from bad steric interactions with AChE. In addition, many of the substituents on the benzyl ring which result in low activity could be explained by their inability to adopt the bioactive conformation. However, in cases such as 2-napthyl which is inactive, it is found that this moiety can adopt the correct conformation and is assumed to be inactive due to a steric clash with the enzyme. These results suggest that there is little space around the benzyl group of E2020 when bound to AChE, in agreement with the QSAR model (Equation (13) σ -Hammett electronic parameter for substituent X Only a very poor QSAR could be derived from which no real explanation for activity could be obtained. Dataset 11 contains mainly substituents on position 6 on the aromatic ring and show a limited activity/property range. Unlike for Datasets 7-10, electron-donating substituents are favoured on the benzisoxazole moiety. A qualitative analysis of this series [43] suggests that electron donating substituents favour AChE inhibition, there also appears to be a preference for hydrophobic substituents and that steric size of substituents appear not to be important for activity.
The QSAR models for benzylamines and benzylpiperidines classes of AChE inhibitors show some similarity. Interpretation of these models would suggest these compounds adopt a similar mode of interaction with AChE. The most important effects include an electronic effect exerted by substituents on the aroyl moiety; whereby electron-withdrawing groups are favoured. In addition, as the hydrophobicity of the molecules decreases the AChE activity increases. These changes in hydrophobicity may be related to changes in the hydrophobicity of the X substituents. The benzisoxazoles appear from the limited QSAR to show a difference in the binding of the X substituents as compared with the benzylpiperidines and benzylamines classes. An electron-donating X substituent for the benzisoxazoles has been suggested to be favoured for AChE activity by increasing the electron density on the oxygen atom, which may form a hydrogen bond with the enzyme.
As with the benzylamine class of inhibitors, a similar mode of interaction for the benzylpiperdine class with AChE has been hypothesized. On the basis of this model, rigidification studies of E2020 led to the identification of a potent AChE inhibitor, TAK-147 [40] which is undergoing clinical trials as a therapeutic agent for Alzheimers disease.
Benzisoxazoles
Bioisosteric replacement of the indanone ring in E2020 was attempted using a benzisoxazole moiety in the search of a AChE inhibitor with an improved in vivo profile. This led to identification of CP118590 which is being evaluated in the clinic. A number of analogues (Fig. (15) ) were synthesized in this series [41] [42] [43] .
The qualitative SAR available for these AChE inhibitor classes also suggest that they all share functional groups (aromatic, basic nitrogen and carbonyl groups) which have been shown to be important for activity. However, there is also evidence indicating that there may be a few localised differences in their binding profiles. In particular, there appears to be a difference in the optimal chain length between the basic nitrogen group and carbonyl group for the benzoyl linked to a benzylamine moiety (n=5, m=1, 7 carbon chain length) and benzoyl linked to a benzylpiperidine moiety (n=2, m=1, 6 carbon chain length). These observations suggest that the different environments of the basic nitrogen within these series leads to a different interaction of the benzylamino moiety with AChE. This could also account for differences in effect of Y substituent on AChE inhibition between these two series. For Y=H, a QSAR model were derived to explain the effect of X substituent on AChE activity for Dataset 11 is given in Equation (14) .
Log 1/IC 50 = -1.274 (0.861)σ + 7.987(0.231) (14) reveals that a longer chain between the carbonyl and basic nitrogen as compared to the benzoyl and indanone-benzylpiperidine series. This could not be explained by MSA analysis but suggests a different mode of binding.
were active (IC 50 > 100µM, rat brain AChE) and this led to the hypothesis that either the conformational constraints imposed by the fused ring system of Huperzine A or the steric and/or hydrophobic nature of both of the other rings are important for AChE inhibition.
Huperzine A
Further analogues were synthesized in order to investigate the contributions of the three carbon bridge, endocyclic double bonds and methyl group. An overlay of HupA and ACh suggests that the three carbon bridge in Hup A would not be necessary for activity. However, it was found that the three carbon bridge essential for AChE activity based on the activity of the Hup A analogue (IC 50 =>100µM, rat brain AChE) in Fig. (16A(II) ). This result suggests that ACh and Hup A adopt different modes of binding within the enzyme's active site. Two analogues of HupA (Fig. (16A(III)) ) in which the double bond between C7 and C8 is removed and the C7 methyl is equatorial or axial were synthesized. Both of these analogues were found to exhibit high AChE (equatorial Me (IC 50 =0.9µM) > axial Me (IC 50 =1.6µM)) albeit significantly lower than HupA. In order to understand these results, the steric fields of both the equatorial and axial methyl substituted Hup A analogues were modelled. It was found that equatorial methyl analogue mimics the shape of Hup A better than the axial methyl. The lower affinity of these analogues as compared HupA could be explained by differences in electrostatic potential about 3 carbon bridge [44] .
Huperzine A (5) (Fig. (16) ) represents a new class of potent, reversible AChE inhibitor which is undergoing clinical trials for Alzheimers disease. Understanding the SAR of Huperzine A (HupA) is important in order to find a similar more easily synthesizable AChE inhibitor with a better in vitro (IC 50 =0.07µM, rat brain AChE (44)) and in vivo profile as HupA. Other qualitative SAR data reveals that substitution of C7 methyl with a phenyl leads to inactivity; this has been interpreted as little room being available for substitution on three carbon bridge. Conversion of pyridone to phenyl leads to inactivity suggesting that pyridone moiety can form H bonds with AChE. Replacement of C11-ethylidene with both methyl and propylidene leads to a drop in activity -the former is due lack of van der Waals contacts and latter due to steric size of the substituent which clash with enzyme. Replacement of NH 2 with either NMe 2 or CNH 2 results in inactivity as does conversion of pyridone to methoxypyridine [45] . All these analogues were tested for AChE inhibition using the rat brain and all exhibited activity IC 50 >10µM.
Replacement of pyridone ring with pyrimidone ring leads to poor activity (IC 50 >10µM) as compared to HupA. For pyrimidones, the additional nitrogen has been suggested to be electrostatically unfavourable for activity [46] . No QSAR studies have been published for HupA, however modelling studies have been performed and qualitative SARs derived. These are presented below.
Based on the SAR of HupA, it would appear that hydrophobic and hydrogen bonding interactions with enzyme are important for its activity. Furthermore, an ionizable nitrogen is also required for activity.
To delineate the pharmacophoric elements of Huperzine A [44] , conformational flexibility of aminomethyl substituted pyridones were investigated (Fig. (16A(I)) ). Neither of these compounds A or B
QSAR Summary
based on the use of 2D descriptors. There is no accounting of conformational properties of inhibitors and the fact that inactivity may result from the inability of a molecule to adopt the bioactive conformation. Furthermore, no rationalization of the binding affinities of enantiomers is possible.
Examination of the QSAR models and qualitative SAR data derived suggests that the different classes of AChE inhibitors adopt unique binding modes with the acetylcholinesterase enzyme.
However, generally speaking, it is observed that all inhibitors tend to be of hydrophobic in nature as suggested by the presence of log P in the majority of QSAR models. In addition, it can be seen that all classes of inhibitors contain an ionizable nitrogen although the importance of a basic nitrogen for AChE is not reflected in the QSAR models generated. The prerequisites of hydrophobicity and an ionizable nitrogen for AChE inhibition has since been confirmed by the crystal structure of AChE-inhibitor complexes [20, 47] and enzyme docking studies. Hydrophobicity is a key feature of AChE inhibitors given that the active site of the enzyme is hydrophobic, lined with aromatic aminoacids. The ionizable nitrogen appears to be important for anchoring the inhibitors within the active site via cation-π interaction between the ionized nitrogen and aromatic Trp 84 residue in the enzyme's active site.
It has been well established that the most important factors for a favourable interaction between a drug and its specific biological target are best represented by 3D properties -a 3D geometric fit of the ligand to a binding site (both ligand and target are in low energy conformations), a complement of electrostatic potential surfaces, the formation of charged and/or neutral hydrogen bonds between functional groups and hydrophobic interactions between lipophilic surfaces. Only one example of 3D-QSAR modelling [38, 39] was employed prior to publication of the 3D structure of the AChE.
Molecular Modelling of Acetylcholinesterase Inhibitors
Since the publication of the crystal structures of both the native AChE [20] and the ligand-AChE complexes [47] structure-based drug design approaches and 3D QSAR have been employed to both attempts to design novel AChE inhibitors and rationalize existing SAR for AChE inhibitors. In this Section, enzyme-ligand models will (1) be utilized to provide information about the bioactive conformations, (2) to be employed to rationalize the SAR data and (3) to assess QSAR models for various classes of inhibitors and (4) to be compared to experimental crystal structures (where available).
The common features described above represent very general requirements for AChE inhibitors. The interaction of the different chemical classes are very specific to each class as dictated by the functionality and their 3D positioning within each molecular framework. It is further observed that the molecular framework for each class in its entirety is crucial for activity; localised changes result in fine-tuning of the global inhibitor-enzyme interaction.
Given the structural diversity of AChE inhibitors and the comparison of the individual QSARs for each series, it can be seen that it would be impractical to structurally align all known inhibitors in any unbiased way and generate a meaningful QSAR model.
Advances
in understanding protein-ligand interactions have led to the development of new molecular modelling approaches such as 3D QSAR as typified by COMFA (Comparative Molecular Field Analysis) [48] . Three-dimensional quantitative structure-activity relationships (3D-QSAR) methods that computes steric, electronic and occasionally hydrophobic interactions for a series of ligands on a regular 3D lattice of probe atoms. The quantitative results are tabulated and appropriate statistical methods yield a QSAR equations highlighting key 3D features of the ligand responsible for activity. This approach is extremely sensitive to the initial alignment of the inhibitors under consideration. The alignment effect on the results has been well documented [49] .
The QSAR approaches can be employed to develop guidelines for target synthesis, and, retrospectively to explain unusual SAR data. For the published AChE inhibitors, little evidence exists for the use of QSAR as a predictive tool in the design of novel and/or more potent AChE inhibitors. Despite the vast amount of synthetic efforts invested in searching for AChE inhibitors, there appears to be little QSAR analyses reported in the literature; much of the analysis has been of a qualitative nature. However, the rationalization of physicochemical properties of AChE inhibitors important for enzyme inhibition represents a starting point upon which new and more potent AChE inhibitors can be designed.
Numerous structure-based drug design algorithms have been published [50] . It is beyond the scope of this review to compare and contrast the differences between algorithms and their potential effects on the results of protein-ligand docking studies. For details of One of the limitations of 2D QSAR analysis is that it is more suitable for congeneric series of inhibitors and the docking approaches used for AChE inhibitors, the reader is referred to each paper. In SYSDOC [51] , the need for an additional term to describe charge-transfer interaction was assessed but it was found that this nature of interaction can be implicitly described by Lennard-Jones and H-bonding terms.
greater (IC 50 = 0.0004µM, rat brain AChE) was observed as compared with tacrine (IC 50 = 0.60µM, rat brain AChE). This chain length leads to a distance of approximately 16 Å between ring nitrogens which has been suggested as being favourable in bisquaternary inhibitors for AChE inhibition. Further hybrid analogues of Tacrine with Huperzine A [54] (Fig. 17(II) ) have also been identified as showing improved affinity as compared with tacrine.
Tacrine
The crystal structure of the tacrine-AChE complex was determined at a resolution at 2.5Å [47] . It was found that the aromatic system of THA is stacked against Trp84 in a π-π interaction, its ring nitrogen forms a hydrogen bond with His 440 and its amino nitrogen is bound to a water molecule. The implications of the QSAR models (Equations (1) and (2)) have not been rationalized within this publication.
Benzylamines and BenzylPiperidines
E2020 has been examined in a number of enzymeligand docking studies. Using the SYSDOC software, the protonated form of E2020 were docked into the AChE [55] . Three likely binding sites were identified. Two of the binding sites (Fig. (18) ) show that benzyl group of the benzylpiperidine is positioned deep down in the AChE gorge, interacting through π-π stacking interaction with the aromatic residues Trp 84 and Phe 330. The protonated nitrogen forms a cation-π interaction with Trp 84, the indanone carbonyl forms a hydrogen bond with the enzyme and the phenyl group of the indanone moiety is shown to interact with Trp 279 with the methoxyls exposed to solvent. The difference between the binding sites is the difference in the hydrogen bonding pattern. The third binding site shows E2020 binding in a reverse orientation in which the benzylpiperdine is positioned at the top of the AChE gorge as compared to other binding sites. The two binding modes described above in which the benzylpiperdine is positioned deep in the AChE gorge show agreement with the QSAR models derived for E2020 and its analogues.
The SYSDOC software was employed to examine the binding of Tacrine (THA) to the Torpedo AChE [51] to check whether the software could reproduce the crystal structure of the THA-AChE complex. A low energy complex of tacrine bound to AChE showed good agreement with crystal structure. A second low energy enzyme-docking model was observed for THA; it was found that THA was bound to a second peripheral site (Trp 279) at the opening to AChE gorge. At present there are no crystal structure for this interaction mode of THA with AChE, however this is consistent with the experimental finding of a peripheral site for THA [52] .
On the basis of the crystal structure and the THAAChE docking studies, it was proposed that two tacrine molecules linked by a methylene chain may prove to be more potent than tacrine by allowing binding simultaneously at both the catalytic and peripheral sites [53] . Using molecular modelling docking approaches, it was found that an approximate chain length of 9 methylene units should be favourable for AChE affinity. This analogue (Fig. 17(I) ) and a few others were synthesized and tested for AChE inhibition. It was found that for n=7, an enzyme inhibition of 1000-fold In a second docking study [56] , the enzyme-ligand complexes of Torpedo Californa AChE and E2020 analogues were determined using full forcefield calculations allowing complete conformational flexibility in both the ligand and enzyme.
As with SYSDOC calculations, this energy based docking approach also suggests the possibility of multiple binding modes for E2020. A similar orientation within the AChE active site gorge is observed as shown in Fig. (1 8 ) . However a number of alternate binding modes are also observed of which many show a number of common interactions with the AChE but also some different localised interactions with AChE. An unusual binding mode is observed whereby the E2020 is aligned in the reverse orientation within the binding pocket (indanone moiety at the bottom of the gorge). This orientation has been ruled out given that there is little space for benzyl substituents unlike for the indanone moiety -based on QSAR models (Equation (13)).
could not be explained by either docking or QSAR studies.
In a third docking study [57] the crystal structure of the Torpedo AChE was modified to represent the human AChE. The only differences in the active site residues is the existence of Tyr at 330 rather than Phe in the human AChE. Compounds with either a phthalimide, benzoyl or indanone moiety at one end and benzyl moiety connected to a tertiary ammonium group at the other end were docked into the AChE.
For the phthalimide analogues shown in Fig. (7 ) , the benzyl group is deep in the active site pocket and orthogonal to Trp 84, the carbonyl group of the phthalimide moiety forms a hydrogen bond to Tyr 121 of the enzyme and the phthalimide moiety is at the top of the gorge forming a π-π interaction with Trp 279. The enzyme-ligand models show that electron withdrawing substituents are favoured on aromatic phthalimide since they are exposed to solvent and since they reduce the electron density of the aromatic moiety allowing a stronger interaction with Trp 279. Replacement of aromatic phthalimide with cyclohexane alters conformation and is too bulky leading to its poor activity. There is little space around the benzyl group which explains the inactivity of p-OMe. The o-and mOMe activity results from hydrogen bonding to AChE. When the length m between the ammonium group and benzene ring (Fig. (8 (III) ) is made longer, the activity decreases for m=2 but not for m=3. For the analogue where m=2, bad steric clashes with AChE is observed whereas for more flexible analogue where m=3, a reasonable conformation can be adopted without incurring bad contacts with the enzyme. Replacement of phthalimide with benzoyl or indanone moieties leads to compounds that retain AChE activity. Similar
In this study, the E2020 analogues for which the number of methylene units between the indanone moiety and the benzylpiperidine is 0 or 2 ( Fig. (1 4 ) ) have been docked in AChE in order to rationalize their activity. The activity profile of these E2020 analogues could not be explained by 3D QSAR studies. For n=0, it is found that benzyl group of the benzylpiperidine moiety is at the bottom of the gorge parallel to Trp 84. The lower activity of this compound as compared to E2020 is attributed to the inability of the indanone moiety to interact with Trp 279. The analogue of E2020 where n = 2, has weaker activity than E2020. It was found that this analogue adopts a similar binding orientation within the active site of AChE as E2020 but can not fulfil as many strong interactions as observed with E2020.
The inactivity of the trans-decalin analogue of E2020 was assumed to be result from steric clashes with AChE in QSAR studies. Docking models of this analogue with AChE shows that this compound can be sterically accommodated within the enzyme active site. The inactivity of the trans-decalin analogue of E2020 enzyme-ligand models as observed for phthalimide analogues could explain these observations. bond could be formed between benzoyl C=O and AChE Tyr 121 OH in a low energy conformation thereby explaining its low activity. The inactive analogue in which n=2, no conformation could be obtained where the piperidine and benzoyl moieties could be accommodated sterically within the active site of AChE. Docking of the 3-arylpropenamide series (Fig. (9 ) ) reveals that their vinyl moiety and not the benzene ring interacts with Trp 279. The higher activity of the acetyl group at R as compared to H is suggested to have resulted from favourable van der Waals interaction of acetyl methyl group with AChE. No hydrogen bond between the acetyl group and AChE was observed, which was suggested to explain the higher activity by QSAR models (Equation (9)).
For benzylpiperidines with an indanone moiety (Fig.  (1 4 ) ), a similar model of enzyme-ligand interaction as with benzoyl series was observed. For benzylpiperidines with a phthalimide group (Fig. (1 3 )) , an extra carbon between phthalimide and piperidine is required to allow the molecule to adopt a low energy conformation which can adopt a similar mode of interaction to its benzoyl and indanone equivalents.
Representative compounds of the benzylpiperidine series were also docked into AChE. For the benzoylpiperidine analogues (Fig. (1 2 )) , a model of their interactions with AChE shows that the benzoyl group interacts with Trp 279, the carbonyl moiety forms a hydrogen bond with Tyr 121 and benzyl group with Trp 84. For the latter interaction, a stacking interaction with Trp 84 is observed for benzylpiperidine whereas an orthogonal interaction was observed for the N-alkyl class. This result explains the difference in the SAR for the aromatic substituents (Y) between these two series. Furthermore, the piperidine nitrogen was found to be shifted 1.5 Å closer to the peripheral site as compared to the equivalent nitrogen in benzylamine series. This explains the differences in optimal chain length for the two series as observed in the qualitative SAR analysis.
The crystal structure of E2020 bound to AChE was recently published [58] , after the publication of the enzyme-docking studies described above. It was found that E2020 binds along the active site gorge. Principal interactions with the enzyme occur through the benzyl, piperidine nitrogen and indanone moieties (Fig. (1 9 ) ) which shows agreement with SAR and enzyme-ligand docking studies. The main interactions are hydrophobic and stacking in nature and are observed with the conserved aromatic residues which line the gorge. Interestingly, E2020 forms no direct contact with the protein via hydrogen bonds/salt bridges; all hydrogen bonds are mediated via water molecules. The role of solvent is shown to be important and was not accounted for in the simulated ligand-enzyme models.
For analogues where the chain length between the benzoyl group and piperidine is n=3, no hydrogen Fig. (19) . The interactions between E2020 and AChE as observed in the crystal structure (E2020 in Dark Green).
One unexpected observation is that the principal binding site for protonated nitrogen of AChE inhibitors is usually the indole ring of Trp 84. In E2020, it would appear as though Phe 330 may play a key role. The selectivity profile of E2020 for AChE over BuCHE is attributed to interactions with Trp279 and Phe 330. its pharmacophoric elements, this led to several erroneous docking studies [46] . Saxena et al. [59] proposed a carbonyl of HupA points towards oxyanion hole and that the primary group interacts with Glu 199. Ashani et al. [60] suggested that Huperzine NH2 and endo-and exo-cyclic groups interacts with Trp 86 and Tyr 337 in human AChE (Trp 84 and Phe 330 in Torpedo Californa AChE), and that the pyridone heteroatoms interact with aminoacids distal to Tyr 337.
Benzisoxazoles
Molecular dynamics simulations of a benzisoxazole analogue (X= 6-NHCOCH 3 ; Fig. (1 5 ) ) in a solvated active site of the crystal structure of Torpedo Californa AChE was performed [42] . Key interactions observed included a critical interaction between the protonated piperidine and negatively charged side chain of Asp 72 of AChE, a hydrogen bond between the benzisoxazole oxygen and NH of Phe 288, the Nbenzyl group forms an off-center π stacking with Trp 84. Assuming the binding mode in which the protonated nitrogen of the benzisoxazole interacts with Asp 72 in AChE, the acetyl substituent is primarily observed as being exposed to solvent and the benzisoxazole oxygen forms a hydrogen bonds with Phe 288 mediated via water molecule. This enzymeinhibitor model explains the requirement of electrondonating substituents (Fig. (1 5 ) ) on the benzisoxazole ring in the QSAR study (Equation (14)). Electronwithdrawing substituents will increase the electron density on the oxygen of the benzisoxazole ring and thereby allowing a stronger hydrogen bonding interaction with Phe 288 via water.
Using the SYSDOC software [51] , Huperzine A was docked into the crystal structure of the native AChE. In this docking study, no a priori assumption was made about the binding site of Hup A on AChE. It was found that Huperzine A can bind to the bottom of gorge of AChE close to the catalytic domain as well as close to the opening of the gorge near the peripheral site. At the bottom of the gorge, Huperzine A could adopt three different binding modes with AChE as shown in Fig. (2 0 ).
The possibility of three possible catalytic subsites is not fully understood but it has been suggested that lack of solvent or dynamic interactions in such a simulation may be responsible. The low affinity peripheral site has been suggested to be important for the build up concentration of HA at gorge entrance. The HupA-AChE docking model in which Hup A binds close to the catalytic site of AChE has been used successfully to rationalize the SAR of some Hup A analogues.
Huperzine A
After the publication of the studies described above, a 2.5 Å resolution crystal structure of Huperzine A complexed to Torpedo Californa AChE was solved [61] . The crystal structure reveals that despite being such a strong AChE inhibitor, Huperzine A makes few Initial docking studies assumed a plausible orientation for HupA being parallel to AChE based on direct contacts with the enzyme (Fig. (2 1 )) . With three potential donor and acceptor sites on the ligand, it is interesting to observe that only one hydrogen bond is seen between the pyridone oxygen and Tyr 130. This explains the importance of this carbonyl group and why its substitution to methoxy group yields inactivity. The ring nitrogen and protonated nitrogen are hydrogen bonded via solvent to the protein. The protonated amino group interacts with Trp 84 and Phe 330 (Tyr in human AChE allow hydrogen bonding to occur). This observation explains the species difference activity of Huperzine A.
introduced at C10 in HupA (IC 50 =0.002µm, Fetal Bovine Serum (FBS) AChE); the corresponding equatorial methyl was observed to decrease activity by 1.5-fold (IC 50 =0.03µm, FBS AChE) . Substituents larger than methyl were found to lead to a drop in activity -the implication being that there was a steric clash between the inhibitor and AChE. Docking studies [62] reveals that axial methyl at C10 position of HupA points towards a small hydrophobic pocket whilst the C10 equatorial faces into a hydrophilic pocket. This additional axial methyl group at C10 increases the logP of molecule and results in favourable additional hydrophobic binding interactions with enzyme as compared to HupA. In general, hydrophobic interactions with aromatic residues in active site of AChE are observed. There appears to be little room for additional groups on Huperzine A without resulting in steric clashes with the enzyme. The crystal structure of the AChE and Huperzine A has been used to explain the SAR of Huperzine A and its analogues. Interestingly as with other AChE inhibitors, no binding to the peripheral site was observed in the crystal structure.
On basis of crystal structure, the pyridone ring of HupA was replaced by catechol and phenol moieties [63] . It was found that although these analogues are predicted on the basis of the crystal structure of HupAAChE to be active, they were both found to be inactive (Ki > 60µM, FBS AChE). This observation can not readily be explained by SAR or docking studies. It may be speculated that the crystal structure represents one static viewpoint of the interaction of an inhibitor with the enzyme and that role of solvent within the active site is not understood. C10 analogues of HupA were synthesized and tested for their ability to inhibit AChE [62] . A 8-fold activity increases when an axial methyl group was
Miscellaneous AChE Inhibitors
Even with the crystal structure of AChE-inhibitor complexes, the problem of predicting AChE -inhibitor interactions for new chemical series is complicated by the flexibility of the ligands and enzyme, the role of solvent and the size of the AChE active site. Enzymedocking models have been shown in general to be able to provide a reasonable prediction of 'likely' binding mode of inhibitors such as E2020 and Huperzine A as compared to the crystal structure. A priori assumptions about the nature of an inhibitor-AChE interactions may lead to erroneous models as observed with the initial docking studies of Huperzine A. In these models, it was assumed that Huperzine A adopts a similar binding mode to ACh and subsequently, the docking studies show a very different interaction of HupA with the enzyme than observed in the crystal structure. Interestingly, solvent has been shown to be important in mediating interactions between inhibitors such as E2020 and Huperzine A and the enzyme in the crystal structure; and its role is often ignored in modelling studies.
Finally, a 3D QSAR COMFA study has been reported for a number of different chemical classes of AChE inhibitors [64] . The alignment of the three inhibitors -edrophonium, tacrine and decathonium in the AChE active site has been employed as a template upon which other structurally analogous AChE inhibitors have been superimposed.
A total of 60 AChE inhibitors, including edrophonium, neostigmine and physostigmine, were structurally aligned on the basis of the knowledge of several crystal inhibitor complexes. These aligned compounds were then subject to COMFA analysis. A cross-validated correlation r 2 of 0.93 was obtained. The COMFA steric fields were found to explain the differences in the AChE activity of the inhibitors. The steric contours observed are compatible with the active site environment -unfavourable steric regions are occupied by His 440, Ser 226, Glu 199, Ser 200 and Phe 288 whereas favourable steric regions do not coincide with residues from the enzyme. The electrostatic contours were found also to correlate well with regions in the active site of AChE.
The enzyme-based models have also been useful in rationalizing the QSAR models generated in order to understand further the AChE-inhibitor interactions. For example, the activity profile of E2020 analogues in which the length of the chain (n) was varied between the indanone moiety and piperidine ring could not be accounted for using 2D or 3D QSAR approaches. Whereas protein-docking models offered a reasonable explanation. Such information available from QSAR and enzyme-docking models has been used successfully to predict more potent analogues within a particular series. There are however examples whereby enzymedocking models have been unsuccessful at explaining the activity profiles of compounds.
Development of such a COMFA model would be extremely difficult in the absence of crystal structures of different AChE-inhibitor complexes. Furthermore, the predictivity of such a model will be confined to chemical series employed in the study or limited to new series which can bind within the same region of the binding site. The authors suggest that docking algorithms may be employed in the identification of new chemical series of AChE inhibitors and 3D QSAR models can be employed to prioritize compounds for synthesis and testing. The rationale for this type of approach is based on the premise that the scoring functions in docking algorithms to prioritize active compounds are poor and that the 3D QSAR models may be better. However, no evidence is provided in this publication to confirm this statement and no new chemical classes are suggested as potentially potent AChE inhibitors.
The existence of a crystal structure has been employed successfully and unsuccessfully to design more potent analogues of known inhibitors e.g. tacrine and Huperzine A, respectively. It must realised that the crystal structure of inhibitor-AChE complexes offers a static representation of enzyme-inhibitor binding. However, it is observed that the structure of AChE does not appear to undergo significant conformational changes upon binding various sizes of inhibitors. Therefore, the crystal structure represents a good starting point for designing new AChE inhibitors.
Summary of Molecular Modelling of Acetylcholinesterase Inhibitors.
Crystallographic studies have shown that the AChE active site is a deep narrow gorge lined by 14 aromatic residues which penetrates into the enzyme widening its base where the catalytic triad featuring Ser200, His440 and Glu327 are positioned. The cocrystallisation of the enzyme with various inhibitors has led to detailed information about the binding modes of various classes of inhibitors.
Despite the availability of the crystal structure of AChE, it is interesting to note that there are no publications which discuss the identification of a new chemical series of AChE inhibitors. Most of the docking studies have focused on AChE inhibitors which were identified prior to the crystal structure of AChE being solved. Techniques such as De Novo drug design, structure-based design in conjunction with combinatorial chemistry approaches may be the future of identifying new AChE inhibitors.
[17] Enz, A.; Amstutz, R.; Roddeke, H.; Gmelin, G. There have been significant effort invested towards the discovery of novel acetylcholinesterase inhibitors during the past decades. During this time, several structural classes of inhibitors have been developed and a few have undergone human clinical trials and have been marketed for a variety of diseases. The pursuit of inhibitors for human acetylcholinesterase continues with the aim of identifying drugs with a more attractive biological and/or chemical profile to currently marketed drugs. With detailed knowledge about AChE inhibitor-enzyme binding modes from QSAR models, enzyme-docking models and crystallography, new chemical classes of inhibitors may be designed in the future, specially from De Novo design and hybrids.
